DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex: AXK) announced today that it has concluded a technical development project with Becton, Dickinson and Company (“BD”) (NYSE: BDX). Accelr8’s technology met formal testing requirements for identification of a subset of relevant species of bacteria. However, BD advised the Company that it has decided to decline an associated exclusive technology license option. At any time, BD has numerous new product opportunities, and prioritizes projects on the basis of decision criteria that are not limited to technical factors.
